HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma

Histone deacetylase 6 (HDAC6) correlates with poor/better survival in cancers. This study was designed to investigate the correlation of HDAC6 expression and renal cell carcinoma (RCC) patients.

A total of 45 fresh RCC samples and 132 paraffin embedded tissues as well as their corresponding adjacent non-tumor tissues were collected from surgical excision. The qRT-PCR, western blotting analysis and immunohistochemically analysis were performed to detect the expression of HDAC6. And Kaplan-Meier curves analysis and Cox proportional hazards model was used to analysis patient survivals as well as to adjust for stratification factors.

The experimental results demonstrated that HDAC6 mRNA expression level was significantly upregulated in RCC tissues compared with adjacent non-tumor tissues, and its expression was correlated with histologic grade and poor overall survival of RCC patients. RCC patients with higher HDAC6 expression showed relative poor survival. Moreover, both HDAC6 expression and histologic grade correlated with RCC prognosis, and high HDAC6 expression was an independent, poor prognostic factor in patient with RCC.

These analyses showed high HDAC6 expression was an independent, poor prognostic factor in patient with RCC, and HDAC6 could serve as a biomarker of RCCs prognostic and an indicator for RCC progression.

Cancer biomarkers : section A of Disease markers. 2016 Jan 20 [Epub ahead of print]

Zijian Zhang, Yanwei Cao, Weiming Zhao, Lei Guo, Wanpeng Liu

Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China., Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shangdong, China., Department of Reproductive Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.